PAVE Library: relevant scientific publications and media coverage

WEBSITE

- *P. vivax* information hub: EN | SPA
- Vivax malaria Study Database: EN | SPA
- The Partnership for Vivax Elimination: EN | SPA
- Tafenoquine Roll-Out Study (TRuST): EN | SPA | PT
- Peru feasibility study: EN | SPA
- Colombia G6PD Pilot Educational Program (PEP): EN | SPA

SCIENTIFIC PUBLICATIONS

**Publications on Radical Cure (EN):**
- Malaria Journal: Challenges for achieving safe and effective radical cure of *Plasmodium vivax*: a round table discussion of the APMEN Vivax Working Group (2017)
- Towards the elimination of *Plasmodium vivax* malaria: Implementing the radical cure (2021)
- The prevention and treatment of *Plasmodium vivax* malaria (2021)
- Primaquine for *Plasmodium vivax* radical cure: What we do not know and why it matters (2021)

**Publications on Radical Cure in Latin America (EN):**
- Towards one standard treatment for uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* malaria: Perspectives from and for the Peruvian Amazon (2021)

**Evidence on primaquine (EN):**
- The Lancet Infectious Diseases: Primaquine dose and the risk of haemolysis in patients with uncomplicated *Plasmodium vivax* malaria: a systematic review and individual patient data meta-analysis (2023)
- The Lancet Infectious Diseases: Effect of primaquine dose on the risk of recurrence in patients with uncomplicated *Plasmodium vivax*: a systematic review and individual patient data meta-analysis (2023)

**Evidence on tafenoquine (EN):**
**New England Journal of Medicine:** Tafenoquine versus Primaquine to Prevent Relapse of *Plasmodium vivax* Malaria (2019)

**Pubmed:** Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with *Plasmodium vivax* malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial (2021)

**The Lancet Child & Adolescent Health:** Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with *Plasmodium vivax* malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial (2022)

**The Lancet:** Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of *Plasmodium vivax* malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study (2023)

**Additional publications on tafenoquine (EN):**

- Cochrane Library: Tafenoquine for preventing relapse in people with *Plasmodium vivax* malaria (2020)
- PloS Medicine: Estimated impact of tafenoquine for *Plasmodium vivax* control and elimination in Brazil: A modelling study (2021)
- PloS Medicine: Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study (2021)

**Evidence on the G6PD test (EN):**

- PloS One: Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity (2018)
- PLoS Neglected Tropical Diseases: Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil (2021)
- MBPI: Assessing the Operational Feasibility of Integrating Point-of-Care G6PD Testing into Plasmodium vivax Malaria Management in Vietnam (2023)

**Additional publications on the G6PD test (EN):**

- Malaria Journal: Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation (2021)
- PloS Neglected Tropical Diseases: Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study) (2021)
- Malaria Journal: Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia (2022)
**EVIDENCE BRIEFS**

- Pediatric treatment for *P. vivax* malaria: new positive data: EN | SPA | PT
- New treatment for *P. vivax* malaria may benefit Brazilian public health: EN | SPA | PT
- Evaluation of a point-of-care test for G6PD deficiency in Brazil: EN | PT
- Point-of-care G6PD diagnostics: EN | SPA | PT

**MEDIA – ABOUT PAVE**

- New Partnership launched to accelerate elimination of relapsing *P. vivax* malaria that poses a risk to an estimated 2.5 billion people worldwide: EN
- Partnership for Vivax Elimination (PAVE) Feasibility Studies and Operational Research: EN | SPA
- PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria: EN

**MEDIA – ABOUT P. VIVAX IN LATIN AMERICA**

- What does it take to eliminate malaria?: PT
- Exploring new tools for *P. vivax* elimination in Brazil: EN | PT
- PAVE Regional Meeting Highlights: 2020: EN | SPA; 2021: EN | SPA | PT; 2022: EN | SPA | PT

**MEDIA – ABOUT TQ & G6PD TEST**

- Preparing the ground in the Brazilian Amazon: PT
- New medicine to treat malaria starts to be used in Amazonas: EN
- PATH and SDB announce partnership to advance diagnostic test critical for malaria treatment and elimination: EN

**MEDIA – REGULATORY MILESTONES**

- US FDA approves Krintafel (tafenoquine) for the radical cure of *P. vivax* malaria: EN
- Kozenis (tafenoquine) approved by Australian TGA for the radical cure of *P. vivax* malaria: EN
- Brazil becomes first malaria-endemic country to approve single-dose tafenoquine (Kozenis) for radical cure of *P. vivax* malaria: EN
- New single-dose medicine to prevent relapse of *P. vivax* malaria just approved in Peru: EN | SPA
- Single-dose Kozenis (tafenoquine) approved for children with *Plasmodium vivax* malaria by Australian Therapeutic Goods Administration: EN | SPA | PT
- STANDARD G6PD Test receives regulatory approval by the Australian Therapeutic Goods Administration: EN
- Colombia approves single-dose medicine to prevent relapse of P. vivax malaria: EN | SPA | PT
- Brazil’s Unified Health System incorporates tafenoquine as a treatment for malaria: EN | PT
- Brazil becomes the first malaria-endemic country to register single-dose tafenoquine for children with relapsing malaria: EN | SPA | PT

**MEDIA – FEASIBILITY STUDIES**

- First real-world use of new protocol for *P. vivax* case management in Brazil – a Health Ministry and MMV collaboration: EN
- Peru feasibility study: First patient, First visit: EN